Pathstone Family Office, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Pathstone Family Office, LLC
- $15.6 Billion
- Q3 2023
A detailed history of Pathstone Family Office, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Pathstone Family Office, LLC holds 1,240 shares of ALNY stock, worth $308,363. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,240Holding current value
$308,363% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
585Shares Held
104MCall Options Held
2.82MPut Options Held
1.75M-
Capital World Investors Los Angeles, CA12.8MShares$3.18 Billion0.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$2.98 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY9.03MShares$2.24 Billion0.03% of portfolio
-
Wellington Management Group LLP Boston, MA7.21MShares$1.79 Billion0.2% of portfolio
-
Baillie Gifford & CO6.62MShares$1.65 Billion0.78% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...